RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
381.17 |
uV |
37.99 |
93.06 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
b-wave amplitude ERG |
108453 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
514.67 |
uV |
47.85 |
117.21 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
b-wave amplitude ERG |
108455 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
587.83 |
uV |
53.2 |
130.31 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
b-wave amplitude ERG |
108456 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
11.68 |
uV |
2.42 |
8.03 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
a-wave amplitude ERG |
108465 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
71.37 |
uV |
8.23 |
27.3 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
a-wave amplitude ERG |
108466 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
137.5 |
uV |
12.91 |
42.82 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
a-wave amplitude ERG |
108469 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
270.09 |
uV |
34.35 |
113.93 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
b-wave amplitude ERG |
108477 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
410.09 |
uV |
45.37 |
150.48 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
b-wave amplitude ERG |
108481 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
15.46 |
uV |
4.1 |
10.04 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
a-wave amplitude ERG |
108488 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
24.73 |
uV |
6.11 |
14.97 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
a-wave amplitude ERG |
108489 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
80.6 |
uV |
11.3 |
27.68 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
a-wave amplitude ERG |
108490 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
188.33 |
uV |
15.56 |
38.11 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
a-wave amplitude ERG |
108493 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
605.83 |
uV |
62.69 |
153.56 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
b-wave amplitude ERG |
108505 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
201.67 |
uV |
18.19 |
44.56 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
a-wave amplitude ERG |
108444 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
56.16 |
uV |
17.2 |
42.13 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
b-wave amplitude ERG |
108452 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
579.0 |
uV |
50.99 |
124.9 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
b-wave amplitude ERG |
108457 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
389.91 |
uV |
52.11 |
172.83 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
b-wave amplitude ERG |
108480 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
71.98 |
uV |
18.54 |
45.41 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
b-wave amplitude ERG |
108500 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
385.17 |
uV |
61.99 |
151.84 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
b-wave amplitude ERG |
108501 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
429.5 |
uV |
66.11 |
161.94 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
b-wave amplitude ERG |
108502 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
6.38 |
uV |
1.4 |
3.43 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
a-wave amplitude ERG |
108440 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
155.28 |
uV |
13.68 |
33.51 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
a-wave amplitude ERG |
108443 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
44.02 |
uV |
13.47 |
44.67 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
b-wave amplitude ERG |
108476 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
334.55 |
uV |
43.36 |
143.81 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
b-wave amplitude ERG |
108478 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
166.85 |
uV |
19.57 |
47.94 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
a-wave amplitude ERG |
108492 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
25.21 |
uV |
4.23 |
10.36 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
a-wave amplitude ERG |
108441 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
88.5 |
uV |
12.52 |
30.67 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
a-wave amplitude ERG |
108442 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
5.17 |
uV |
1.18 |
3.91 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
a-wave amplitude ERG |
108464 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
104.17 |
uV |
12.63 |
41.89 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
a-wave amplitude ERG |
108467 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
118.51 |
uV |
12.59 |
41.76 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
a-wave amplitude ERG |
108468 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
119.33 |
uV |
19.43 |
47.59 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
a-wave amplitude ERG |
108491 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
511.83 |
uV |
65.06 |
159.36 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
b-wave amplitude ERG |
108504 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
216.67 |
uV |
19.46 |
47.67 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
a-wave amplitude ERG |
108445 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
440.0 |
uV |
43.67 |
106.97 |
electroretinography |
cornea |
0.0 |
subretinal injection |
30 |
min |
CHPG |
b-wave amplitude ERG |
108454 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 11 |
351.91 |
uV |
47.74 |
158.34 |
electroretinography |
cornea |
0.0 |
subretinal injection |
2 |
days |
CHPG |
b-wave amplitude ERG |
108479 |
3123 |
RCS-rdy+ p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-Chloro-5-hydroxyphenylglycine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
0 days
| 6 |
485.67 |
uV |
73.15 |
179.18 |
electroretinography |
cornea |
0.0 |
subretinal injection |
10 |
days |
CHPG |
b-wave amplitude ERG |
108503 |
3123 |